Neuberger Berman Group
CRSP icon

Neuberger Berman Group’s CRISPR Therapeutics CRSP Stock Holding History

Neuberger Berman Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-3,240
Closed -$395K – 1769
2021
Q1 		$395K Buy
3,240
+648
+25% +$97.8K ﹤0.01% 1538
2020
Q4 		$407K Buy
2,592
+153
+6% +$18.1K ﹤0.01% 1444
2020
Q3 		$211K Buy
+2,439
New +$216K ﹤0.01% 1544

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Neuberger Berman Group's CRSP Position: Q2 2021 in Review

Neuberger Berman Group sold out of CRISPR Therapeutics (CRSP) in Q2 2021, closing a stake of 3,240 shares — an estimated $395K sold.

Neuberger Berman Group first reported a position in CRSP in Q3 2020 and held it in 3 quarters. The position peaked at $407K in Q4 2020. 498 funds tracked by Wall St. Rank hold CRSP as of Q2 2021.

  • Neuberger Berman Group reported no remaining CRISPR Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Neuberger Berman Group sold 3,240 CRISPR Therapeutics shares in Q2 2021, an estimated $395K.
  • Neuberger Berman Group first reported a position in CRISPR Therapeutics in Q3 2020 and held it in 3 quarters.
  • Neuberger Berman Group's CRISPR Therapeutics position peaked at $407K in Q4 2020.
  • 498 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2021.

Based on Neuberger Berman Group's 13F filing for Q2 2021, filed 13 Aug 2021.